Compare · ELTX vs NVO
ELTX vs NVO
Side-by-side comparison of Elicio Therapeutics Inc. (ELTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 691.3x ELTX ($283.4M).
- Over the past year, ELTX is down 46.6% and NVO is down 43.0% - NVO leads by 3.6 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 3 for ELTX).
- Company
- Elicio Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.11-72.29%
- $43.91+0.06%
- Market cap
- $283.4M
- $195.92B
- 1M return
- -62.40%
- -4.14%
- 1Y return
- -46.62%
- -43.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 4
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELTX
- Elicio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
- B. Riley Securities initiated coverage on Elicio Therapeutics with a new price target
- Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology
- SEC Form 10-Q filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Elicio Therapeutics to Present at the Bank of America Healthcare Conference
- Amendment: SEC Form 10-K/A filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Reports Inducement Grants
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S